Characterisation of an Atrx Conditional Knockout Mouse Model: Atrx Loss Causes Endocrine Dysfunction Rather Than Pancreatic Neuroendocrine Tumour

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Gaspar, TB (Author) Other; Macedo, S (Author) Other; Sa, A (Author) Other; Soares, MA (Author) Other; Rodrigues, DF (Author) Other; Sousa, M (Author) Other; Mendes, N (Author) Other; Martins, RS (Author) Other; Cardoso, L (Author) Other; Borges, I (Author) Other; Canberk, S (Author) Other; Gartner, F (Author) Other; Miranda-Alves, L (Author) Other; Sobrinho-Simoes, M (Author) Other; Lopes, JM (Author) FMUP; Soares, P (Author) FMUP; Vinagre, J (Author) Other

Journal

Title: Cancers

Vol. 14

Final page: 3865

ISSN: 2072-6694

Publisher: MDPI

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00X-1ZV

DOI: 10.3390/cancers14163865

Abstract (EN): Simple Summary ATRX and DAXX mutations occur in 30-40% of pancreatic neuroendocrine tumours (PanNETs), and there are no reports in the literature of any genetically engineered mouse model (GEMM) evaluating the effect of Atrx disruption as a putative driver event on PanNET initiation. We created a novel GEMM with Atrx conditional disruption in beta cells. We observed that this genetic alteration, per se, was not tumourigenic, but we reported novel roles of Atrx on endocrine function, which resulted in dysglycaemia and the exacerbation of inflammageing (increased pancreatic inflammation and hepatic steatosis). ATRX is a chromatin remodeller that maintains telomere homeostasis. Loss of ATRX is described in approximately 10% of pancreatic neuroendocrine tumours (PanNETs) and associated with poorer prognostic features. Here, we present a genetically engineered mouse model (GEMM) addressing the role of Atrx loss (Atrx(KO)) in pancreatic beta cells, evaluating a large cohort of ageing mice (for up to 24 months (mo.)). Atrx loss did not cause PanNET formation but rather resulted in worsening of ageing-related pancreatic inflammation and endocrine dysfunction in the first year of life. Histopathological evaluation highlighted an exacerbated prevalence and intensity of pancreatic inflammation, ageing features, and hepatic steatosis in Atrx(KO) mice. Homozygous floxed mice presented hyperglycaemia, increased weights, and glucose intolerance after 6 months, but alterations in insulinaemia were not detected. Floxed individuals presented an improper growth of their pancreatic endocrine fraction that may explain such an endocrine imbalance. A pilot study of BRACO-19 administration to Atrx(KO) mice resulted in telomere instability, reinforcing the involvement of Atrx in the maintenance of beta cell telomere homeostasis. Thereby, a non-obese dysglycaemic GEMM of disrupted Atrx is here presented as potentially useful for metabolic studies and putative candidate for inserting additional tumourigenic genetic events.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 20